Medical isotope developer IsoRay Medical is reporting the launch of a study to evaluate the use of cesium-131 brachytherapy seeds for non-small cell lung cancer (NSCLC).
The Richland, WA-based firm said that a number of institutions and physicians are working to collect scientific data on the use of cesium-131 internal radiation therapy in conjunction with surgery for NSCLC.
Related Reading
IsoRay revenue dips in FY10, September 28, 2010
IsoRay to distribute Hologic's GliaSite, June 23, 2010
IsoRay sales slip, net loss narrows, May 12, 2010
IsoRay sales grow in Q2, February 17, 2010
IsoRay adds VP, January 27, 2010
Copyright © 2010 AuntMinnie.com